Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics

被引:95
作者
Roth, W
Fontana, A
Trepel, M
Reed, JC
Dichgans, J
Weller, M
机构
[1] UNIV TUBINGEN,SCH MED,DEPT NEUROL,MOL NEUROONCOL LAB,D-72076 TUBINGEN,GERMANY
[2] UNIV ZURICH HOSP,DEPT INTERNAL MED,CLIN IMMUNOL SECT,ZURICH,SWITZERLAND
[3] LA JOLLA CANC RES FDN,LA JOLLA,CA 92037
关键词
malignant glioma; CD95 (Fas/APO-1); apoptosis; chemotherapy; synergy;
D O I
10.1007/s002620050355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant glioma cells are susceptible to CD95(Fas/APO-1)-mediated apoptosis triggered by agonistic antibody. Here we examined the proapoptotic effects of the natural CD95 ligand, a cytotoxic cytokine homologous to tumor necrosis factor, on malignant glioma cell lines LN-229, LN-308 and T98G. We assessed whether glioma cell killing is synergistically enhanced by cotreatment with CD95 ligand and chemotherapeutic agents, including doxorubicin, carmustine, vincristine, etoposide, teniposide, 5-fluorouracil and cytarabine. Synergy was examined at low concentrations of cytotoxic drugs and CD95 ligand with a defined effect level (IC15). Short-term-cytotoxicity assays showed prominent killing of the glioma cells by CD95 ligand but not by the drugs at relevant concentrations. CD95 ligand-induced apoptosis in the acute toxicity paradigm was augmented by doxorubicin and vincristine. Growth-inhibition assays revealed prominent synergy between CD95 ligand and all drugs examined. The best synergy was obtained with CD95 ligand and doxorubicin, vincristine or teniposide. The strong synergistic antiproliferative effects were observed at much lower concentrations of CD95 ligand and cytotoxic drugs than the moderate synergistic acute cytotoxic effects. All cell lines examined express the Bcl-2 protein. LN-229 has partial wild-type p53 activity. T98G has mutant p53. LN-308 has a deleted p53 gene and lacks p53 protein expression. Thus, synergistic effects of CD95 ligand and cytotoxic drugs were observed in cell lines exhibiting two features thought to play a role in the chemoresistance of human malignant glioma cells: loss of wild-type p53 activity and acquisition of bcl-2 expression. Ectopic expression of murine bcl-2 conferred partial protection from CD95 ligand and drugs when administered alone but did not interfere with the mechanisms underlying the synergistic effects of CD95 ligand and chemotherapeutic drugs.
引用
收藏
页码:55 / 63
页数:9
相关论文
共 43 条
[1]  
ALDERSON LM, 1995, CANCER RES, V55, P999
[2]  
ALEXANDER RB, 1987, CANCER RES, V47, P2403
[3]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[4]   THE P53 GENE AND ITS ROLE IN HUMAN BRAIN-TUMORS [J].
BOGLER, O ;
HUANG, HJS ;
KLEIHUES, P ;
CAVENEE, WK .
GLIA, 1995, 15 (03) :308-327
[5]   CERAMIDE SYNTHASE MEDIATES DAUNORUBICIN-INDUCED APOPTOSIS - AN ALTERNATIVE MECHANISM FOR GENERATING DEATH SIGNALS [J].
BOSE, R ;
VERHEIJ, M ;
HAIMOVITZFRIEDMAN, A ;
SCOTTO, K ;
FUKS, Z ;
KOLESNICK, R .
CELL, 1995, 82 (03) :405-414
[6]   APOPTOTIC SIGNALING THROUGH CD95 (FAS/APO-1) ACTIVATES AN ACIDIC SPHINGOMYELINASE [J].
CIFONE, MG ;
DEMARIA, R ;
RONCAIOLI, P ;
RIPPO, MR ;
AZUMA, M ;
LANIER, LL ;
SANTONI, A ;
TESTI, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1547-1552
[7]   SUPPRESSION OF APOPTOSIS IN A CYTOTOXIC T-CELL LINE BY INTERLEUKIN 2-MEDIATED GENE-TRANSCRIPTION AND DEREGULATED EXPRESSION OF THE PROTOONCOGENE BCL-2 [J].
DENG, G ;
PODACK, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2189-2193
[8]  
FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO
[9]  
2-S
[10]   APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD [J].
FISHER, DE .
CELL, 1994, 78 (04) :539-542